Member Info for Num4

437,660. In till the end. Target 500k.

I think the direction of the slides this time around pointed to the pathway for another company to be the next Nimbus. I say another company because it is also clear that we won't go beyond P1b.

It has clearly shown the value of such compound in this space and emphasized the increased scientific interest.

I think we have build the foundation that supports a licence, when that happens is between now and next December.

SRA737 license is overdue but the 1000 pages comment is the reason, if John thinks it'll be licensed then I trust in that assessment.

1802 will be retainer for a second pop at a license with agreements in place to share all data on 1801 as it progresses through a phase 2 with another company.

In the background full blown takeover always being assessed.

I'd like to see us behaving a bit more like a clinical stage drug company with a potential £4billion+ product.

The more I think about this RF situation the more I lean towards this being very unlike the Sareum I've known for 14years ish. Market placing was always the way until the HMWI's turned up. We always expected these investors to up the funding when the time came for P1a/b I think it was insinuates a few times from Parker that they have full support from the HMWI's.

So why go to RF? Perhaps these investors are too in the know for them to be allowed to commit more funds, the placing option will quickly give a big chunk away so they have opted for the drip funding until the license or buyout is concluded...

Tim and John have always touted shareholder value and over the years we have seen it, you just have to sell at the right time. I do believe we are coming to a happy ending though, previously Tim would raise enough to progress other programs aswell, this time it's 100% all in on tyk2/jak1, and for very good reason.

All I'm saying, after all these years I've not seen this strategy before with Sareum, and I don't for one second believe they could get a placing away, for a 100% owned autoimmune potential blockbuster. With closely related cancer angle uncle.

Remember the days of substitute salary for shares to preserve cashflow, not a decision taken easily but showed the commitment to final success of the business, they aren't about to throw this away, trust that it has been done for the right reason, ultimately, to build shareholder value.

Which seems a crazy statement to make considering the current market cap, but I think Tim thought the market would have reacted more positively to P1a approvals etc, funding hampered that and now funding is keeping it lower.

Overall I trust we have the right people on the table to get the best result for Sareum and it's Shareholders.

What the RNS doesn't clearly point out is that once daily is sufficient. A once daily capsule for psoriasis treatment on the advance. Big pharma have whole departments monitoring breakthrough therapies, Sareum will be on that list.

Good point Sflf, between 20% and 25% I think you're correct.

This should now see a change in market sentiment leading up to a license for 1801 with any SRA737 license welcome to progress this compound without further delay. Don't forget we have been told by the chairman that a queue had formed for these discussions.

With Sareum, we aren't a big company with big overheads and wild salaries, it's all very measured and calculated which is what you would expect from 2 men that design molecules to fight back against cancer and autoimmune disease.

There really isn't a better place for your cash at this moment in time.

Yes we all want more this and more of that, but more costs money. They strongly believe their compounds will be successful so I'll back their industry experience and a 10+ year work process to get 1801 into the clinic. It's almost like robbery, piggy backing on the immense skill and hard work of 2 individuals via shares in their company.

We will be rewarded for our patience in due course. GLA

MAJ, go look at the GDR one and then the Sareum one and objectively tell us the difference. Your not comparing apples with apples here.

I Trust the board with their decision.

The thing with Sareum and investing in such shares is that you have to fully trust the 2 people who started the company, have the technical expertise and have not wavered in their efforts to treat cancer and other autoimmune disease. You have been investing in them because unlike a PH client, you won't know when to get in to maximise gain with little effort or real investment. At these early stages they trade while we invest. When the balance changes is when we, the normal punter, make the life changing gains.

Things can change quickly in biotech and Sareum are now in that lane, instead of tip toeing to the starting line, the gun has gone, but it's not a 100m race, it's a relay, who will we pass the 1801 baton to and will it happen on lap 2 or lap 4. What we do know is, it will happen, let's just enjoy watching this progress and make a little money on the way. There is so much confidence in dual inhibition of Psoriasis because there is so much evidence and biology that this will obviously be more effective. More effective at less dosage, so less side effects is the key. Exactly what 1801 has been "designed" to do.

Speed has not been Sareums fortay, the science has. It's time for 1801 to do the talking now, while Tim, John and all of us investors reap the rewards.

Then when Sareum are long gone, and 1801 is in multiple fast track designations for multiple autoimmune conditions,.you can say, "I invested in the company that made that happen. "

Desamax, what did you ask them? Did they answer your question? I thought it was in relation to the amount of trials waiting on MHRA.

Let's not forget that the COVID route to market had a prerequisite of a clinical stage compound, we're now a clinical stage compound. I'd imagine this has fallen away somewhat now though.

Interested to hear Tim and John comment on this at next meeting.

They did have $574million in cash at end of 2022 though.

This is where Sareum need to decide are we sticking to the business model or playing with the big boys. It would be a complete restructure so I'm certain we will license 1801 before the end of phase 1. As already mentioned, the longer it is left the more they will have to pay, price now and the price and interest after 1b will be very different.

Once our cash position is secured to end of phase 1 then the SP will be released, how good are those investor relationships is the question. We certainly don't want a market placing or another investor for that matter. Unless we are dreaming big. Who knows all guess work at the minute.

Certainly a good time to have something of value in the autoimmune space.

The short answer on SRA737 imo, other chk1 compound's have had many failures and discontinuations over the last 10years, that's why some drugs just takes years to get to market, further clinical research by CRUK helps promote it, and we have a spokesman in CRUK for SRA737. So it is a matter of time until that progresses, as always. It costs us nothing and we have everything to gain, 1801 is the focus though, as previously mentioned, it's a biotech company on its own.

The relationships Parker and Peel have built over the last few years will be progressing now that we are in the clinic. Funding RNS would give the confidence to move this to the next level. I'm sure it's being discussed and hopefully hear something within the next few weeks.

I had the pleasure to talk to Thoth personally on a number of occasions and often exchanged whattsApp messages. Great guy with a true desire to help his fellow citizens. He gave me lots of practical advice over the years and we both had a true belief that what Tim and Co have is a once in a lifetime opportunity, unfortunately his worst fear came true and that it wouldn't be within his lifetime.

Just makes us all think about how we need to live for today and enjoy what time we have.

I'm very pleased to hear he had his daughters at his side, those days at the races will be treasured for a long time. Hopefully the name Richard H. has been involved with getting everything sorted for you/them as he was the only person Thoth trusted with money and investments.

Look forward to the £14 party in honour of Thoth!

Want to know why we really went to OZ...

https://www.gov.uk/government/publications/commercial-clinical-trials-in-the-uk-the-lord-oshaughnessy-review/commercial-clinical-trials-in-the-uk-the-lord-oshaughnessy-review-final-report#part-2-problem-statements-and-significant-actions

Scathing report. At least change will be on the horizon for SDC1802.

Going to post a few links here's to put into perspective what we have with SDC-1801 alone. For those that don't want to look through it all, the short summary is, SDC-1801 is a pharma company on its own.

Best read in order below.

https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01397 (compound 6 is the focus) brepocitinib

https://www.evaluate.com/vantage/articles/news/snippets/pfizer-bows-out-tyk2-race

https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing

https://www.priovanttx.com/pipeline.html

And lastly to wrap to all up. Think about the manpower of Sareum, 2 directors, a chairman and 2 NEDS, now look at this manpower for another tyk2/jak1 ONLY company;

https://www.priovanttx.com/about.html

Perspective. Hand on to these people. You'll not get another opportunity like this.

Https://www.fiercebiotech.com/biotech/bicycle-rides-second-17b-big-pharma-deal-two-months-time-bayer

SKIL platform value is something often overlooked, yet it has produced our tyks and aurora+flt3. With many more in discovery mode. Further strings to the Sareum bow which should make its way into broker valuation figures over the next 12months.

Disappointed with the share price after that pivotal RNS, lack of interest now that funds have been mentioned. Maybe a repeat of summer 2021 on the cards though.

An old published debate between Tim and Don Nicholson on tyk2.

https://www.google.com/url?sa=t&source=web&rct=j&url=http://www.nimbustx.com/wp-content/uploads/2017/10/BioCentury-Innovations-Nimble-Move-10.5.2017.pdf&ved=2ahUKEwii8q2P4uP-AhXhU6QEHeg6BP4QFnoECAsQAQ&usg=AOvVaw1CgUqdpX922rXZ_xtPQw5k

Sareum have been very clear on the strategy, license pre or early clinical. I believe they will have a number of interested parties awaiting the first in human safety data.
Either they license the single compound or the company gets bought out. It's a great time to be invested and the tyk2 market is emerging as a valid therapeutic target with some big figures for sales estimated.
Importantly, we clearly differentiate from existing compounds being tyk2 only. Only time will tell if we improve on efficacy, the science says we will for psoriasis due to dual inhibition.
Not long to go.

Previous patterns are slight rise on morning, dip then off to the races afternoon.
Rinse and repeat for the next few weeks.

Paves the way for the license now, how many big pharma will want something that can compete with BMS and Takeda..Parker going to be busy this year. This should have the HNWI lined up for the extra funding for 1b, sniff of positive 1a and bank roll this until the license.
Doors are being opened on multiple fronts.

Well done everyone!